CATALOGO DEI PRODOTTI DELLA RICERCA

MILELLA, Michele
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 5.495
NA - Nord America 5.299
AS - Asia 3.425
SA - Sud America 89
AF - Africa 83
OC - Oceania 18
Continente sconosciuto - Info sul continente non disponibili 7
AN - Antartide 1
Totale 14.417
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 5.215
CN - Cina 1.701
SG - Singapore 1.208
IT - Italia 823
GB - Regno Unito 815
RU - Federazione Russa 786
FR - Francia 773
IE - Irlanda 701
SE - Svezia 552
DE - Germania 465
FI - Finlandia 298
ID - Indonesia 142
HK - Hong Kong 86
CA - Canada 75
UA - Ucraina 69
BR - Brasile 67
VN - Vietnam 63
NL - Olanda 57
TG - Togo 50
KR - Corea 44
JP - Giappone 35
IN - India 32
PL - Polonia 28
CZ - Repubblica Ceca 24
TH - Thailandia 23
BE - Belgio 19
AU - Australia 17
EG - Egitto 17
AT - Austria 16
IR - Iran 16
MY - Malesia 10
ES - Italia 9
CH - Svizzera 8
EU - Europa 7
PE - Perù 7
PK - Pakistan 7
TR - Turchia 7
AZ - Azerbaigian 6
CL - Cile 6
KG - Kirghizistan 6
LU - Lussemburgo 6
MA - Marocco 6
SK - Slovacchia (Repubblica Slovacca) 6
LV - Lettonia 5
RO - Romania 5
BG - Bulgaria 4
CO - Colombia 4
EC - Ecuador 4
HR - Croazia 4
JO - Giordania 4
LT - Lituania 4
MK - Macedonia 4
PH - Filippine 4
SA - Arabia Saudita 4
UZ - Uzbekistan 4
AM - Armenia 3
DK - Danimarca 3
IL - Israele 3
MX - Messico 3
TN - Tunisia 3
TW - Taiwan 3
ZA - Sudafrica 3
AE - Emirati Arabi Uniti 2
BD - Bangladesh 2
BY - Bielorussia 2
CR - Costa Rica 2
GR - Grecia 2
KH - Cambogia 2
KZ - Kazakistan 2
LA - Repubblica Popolare Democratica del Laos 2
NO - Norvegia 2
PA - Panama 2
CY - Cipro 1
DO - Repubblica Dominicana 1
DZ - Algeria 1
EE - Estonia 1
FK - Isole Falkland (Malvinas) 1
GS - Georgia del Sud e Isole Sandwich Australi 1
GT - Guatemala 1
HU - Ungheria 1
IQ - Iraq 1
KE - Kenya 1
LK - Sri Lanka 1
MD - Moldavia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
PT - Portogallo 1
SC - Seychelles 1
SI - Slovenia 1
SN - Senegal 1
Totale 14.417
Salva come PNG Salva come JPEG
Città #
Chandler 1.264
Singapore 990
Southend 738
Dublin 678
Beijing 341
Woodbridge 333
Ashburn 300
Jacksonville 299
Verona 294
Lawrence 267
Princeton 267
Ann Arbor 197
Sindelfingen 185
Houston 171
Helsinki 153
Redmond 139
Jakarta 137
Wilmington 135
Jinan 134
New York 106
Nanjing 84
Hong Kong 77
Shenyang 76
Milan 70
Munich 66
Hebei 61
Seattle 59
Toronto 51
Lomé 50
Tianjin 49
Ningbo 44
Changsha 37
Seoul 37
Los Angeles 36
Zhengzhou 36
Santa Clara 33
Boardman 31
Guangzhou 31
Haikou 31
Hangzhou 31
Kent 31
Nanchang 30
Dallas 29
Dong Ket 29
Tokyo 29
Amsterdam 27
Taiyuan 27
Washington 27
Moscow 25
Redwood City 25
Taizhou 25
Rome 23
Fuzhou 22
Jiaxing 22
Bangkok 21
Andover 20
Brno 20
Frankfurt am Main 20
Lanzhou 20
London 20
Brussels 19
Chicago 18
Lappeenranta 18
Dongguan 17
Shanghai 17
San Francisco 16
Fairfield 14
Cedar Knolls 12
Falls Church 12
Nuremberg 12
Falkenstein 11
Norwalk 11
Vienna 11
Bologna 10
Ottawa 10
Paris 10
Cairo 9
Cambridge 9
Padova 9
Trento 9
Zanjan 9
Huskvarna 8
São Paulo 8
Boydton 7
Chions 7
Clearwater 7
Este 7
Kochi 7
Laurel 7
Lima 7
The Hague 7
Baku 6
Dearborn 6
Florence 6
Isola della Scala 6
Mehlingen 6
Menlo Park 6
Mumbai 6
Naples 6
Pieve di Soligo 6
Totale 8.999
Salva come PNG Salva come JPEG
Nome #
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers 122
Immunoevolution of mouse pancreatic organoid isografts from preinvasive to metastatic disease 121
Genomic characterization of hepatoid tumors: context matters 118
Immune checkpoint blockade therapy mitigates systemic inflammation and affects cellular FLIP-expressing monocytic myeloid-derived suppressor cells in non-progressor non-small cell lung cancer patients 111
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer 111
Autoantibodies to Ezrin are an early sign of pancreatic cancer in humans and in genetically engineered mouse models 108
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 102
ERK 1/2 phosphorylation is an independent predictor of complete remission in newly diagnosed adult acute lymphoblastic leukemia 101
Molecular heterogeneity assessment by next-generation sequencing and response to gefitinib of EGFR mutant advanced lung adenocarcinoma 101
"Running with cancer": A qualitative study to evaluate barriers and motivations in running for female oncological patients 98
Therapeutic potential of combined BRAF/MEK blockade in BRAF-wild type preclinical tumor models 96
An integrated humoral and cellular response is elicited in pancreatic cancer by alpha-enolase, a novel pancreatic ductal adenocarcinoma-associated antigen 95
Adjuvant Chemotherapy For Resected Non-Small-Cell Lung Cancer: Future Perspectives For Clinical Research 94
Deep vein thrombosis in SARS-CoV-2 pneumonia-affected patients within standard care units: Exploring a submerged portion of the iceberg 94
PTEN status is a crucial determinant of the functional outcome of combined MEK and mTOR inhibition in cancer 94
Interleukin-2 gene transfer into human transitional cell carcinoma of the urinary bladder 93
A phase II study of liposomal irinotecan with 5-fluorouracil, leucovorin and oxaliplatin in patients with resectable pancreatic cancer: the nITRO trial 93
Organisational challenges, volumes of oncological activity and patients' perception during the severe acute respiratory syndrome coronavirus 2 epidemic 90
Sex differences in oncogenic mutational processes 88
Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Pancreatic Cancer: Systematic Review and Still-Open Questions 87
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 85
Long-Term Patient-Centred Follow-up in a Prospective Cohort of Patients with COVID-19 84
Advances towards the design and development of personalized non-small-cell lung cancer drug therapy. 81
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agents. 80
Anti-Angiogenic Drugs and Biomarkers in Non-Small-Cell Lung Cancer: A 'Hard Days Night' 79
Risk Stratification Model for Resected Squamous-Cell Lung Cancer Patients According to Clinical and Pathological Factors 79
Emerging pathways and future targets for the molecular therapy of pancreatic cancer. 78
Circulating autoantibodies to phosphorylated alpha-enolase are a hallmark of pancreatic cancer 77
Pilot study of celecoxib and infusional 5-fluorouracil as second-line treatment for advanced pancreatic carcinoma 77
Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules 77
Immune landscape, evolution, hypoxia-mediated viral mimicry pathways and therapeutic potential in molecular subtypes of pancreatic neuroendocrine tumours 76
Role of next-generation genomic sequencing in targeted agents repositioning for pancreaticoduodenal cancer patients 76
An Italian study on treatment trends and outcomes of patients with stage III pancreatic adenocarcinoma in the gemcitabine era: is it time to change? 75
From Genetic Alterations to Tumor Microenvironment: The Ariadne's String in Pancreatic Cancer 75
Hypofractionated Stereotactic Body Radiation Therapy With Simultaneous Integrated Boost and Simultaneous Integrated Protection in Pancreatic Ductal Adenocarcinoma 74
Prognostic Impact of Preoperative Nutritional Risk in Patients Who Undergo Surgery for Pancreatic Adenocarcinoma 73
Psychological impact of Covid-19 pandemic on oncological patients: a survey in Northern Italy 73
Integrating supportive care into the multidisciplinary management of lung cancer: we can't wait any longer 73
Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples 72
Risk Adapted Ablative Radiotherapy After Intensive Chemotherapy for Locally Advanced Pancreatic Cancer 71
Do immune checkpoint inhibitors need new studies methodology? 70
Efficacy and Toxicity Analysis of mFOLFIRINOX in High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms 69
Prognostic Model for Resected Squamous-Cell Lung Cancer: External Multicenter Validation and Propensity Score Analysis exploring the Impact of Adjuvant and Neoadjuvant Treatment 69
The Italian Rare Pancreatic Exocrine Cancer Initiative 69
Adjuvant Chemotherapy for Non-Small-Cell Lung Cancer 69
Multidisciplinary lifestyle intervention to manage pancreatic cancer-related cachexia: a case report 69
Aromatase inhibitors in post-menopausal metastatic breast carcinoma 68
Novel Clinical Prognostic Score Incorporating the Number of Resected Lymph-Nodes to Predict Recurrence and Survival in Non-Small-Cell Lung Cancer. 68
JAK/Stat5-mediated subtype-specific lymphocyte antigen 6 complex, locus G6D (LY6G6D) expression drives mismatch repair proficient colorectal cancer 68
Sequential therapy in metastatic clear cell renal carcinoma: TKI-TKI vs TKI-mTOR. 67
The pattern of hMENA isoforms is regulated by TGF-β1 in pancreatic cancer and may predict patient outcome 67
Exercise prehabilitation in lung cancer: Getting stronger to recover faster 67
Alternative Lengthening of Telomeres (ALT) in Pancreatic Neuroendocrine Tumors: Ready for Prime-Time in Clinical Practice? 67
Cardiotoxicity and Incidence Of Brain Metastases After Adjuvant Trastuzumab for Early Breast Cancer: The Dark Side of the Moon? A Meta-Analysis of The Randomized Trials. 66
FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer 66
Muscle derangement and alteration of the nutritional machinery in NSCLC 65
Autoantibody signature in human ductal pancreatic adenocarcinoma 65
PTEN in Lung Cancer: Dealing with the Problem, Building on New Knowledge and Turning the Game Around 65
Evaluation of nutritional status in non-small-cell lung cancer: screening, assessment and correlation with treatment outcome 65
Molecular predictors of EGFR-mutant NSCLC transformation into LCNEC after frontline osimertinib: digging under the surface 65
Infections and Immunotherapy in Lung Cancer: A Bad Relationship? 65
Clinical Evaluation of the Use of Exemestane as Further Hormonal Therapy after Nonsteroidal Aromatase Inhibitors in Postmenopausal Metastatic Breast Cancer Patients 64
Physical activity and exercise in lung cancer care: will promises be fulfilled? 64
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 63
Capecitabine and celecoxib as second-line treatment of advanced pancreatic and biliary tract cancers. 63
Unmasking the impact of Rictor in cancer: novel insights of mTORC2 complex 63
Liquid Biopsy as Surrogate for Tissue for Molecular Profiling in Pancreatic Cancer: A Meta-Analysis Towards Precision Medicine 63
How the COVID-19 Pandemic Impacted on Integrated Care Pathways for Lung Cancer: The Parallel Experience of a COVID-Spared and a COVID-Dedicated Center 63
Metastatic pancreatic cancer: Is there a light at the end of the tunnel? 62
MDM2 gene amplification as selection tool for innovative targeted approaches in PD-L1 positive or negative muscle-invasive urothelial bladder carcinoma 62
Comprehensive analysis of 34 MiT family translocation renal cell carcinomas and review of the literature: investigating prognostic markers and therapy targets 62
Impact of COVID-19 on Pancreatic Cancer Research and the Path Forward 62
Open radiofrequency ablation as upfront treatment for locally advanced pancreatic cancer: Requiem from a randomized controlled trial 61
Multicenter Retrospective Analysis of Second-Line Therapy after Gemcitabine Plus Nab-Paclitaxel in Advanced Pancreatic Cancer Patients 61
Prognostic impact of alternative splicing-derived hMENA isoforms in resected, node-negative, non-small-cell lung cancer. 60
Characterization of Myeloid-derived Suppressor Cells in a Patient With Lung Adenocarcinoma Undergoing Durvalumab Treatment: A Case Report 60
Pan-cancer analysis of whole genomes 60
Clinical outcomes in patients with metastatic renal cell carcinoma receiving everolimus or temsirolimus after sunitinib 60
Exercise levels and preferences in cancer patients: a cross-sectional study 60
Factors influencing physical activity in cancer patients during oncological treatments: a qualitative study 60
A phase II trial proposal of total neoadjuvant treatment with primary chemotherapy, stereotactic body radiation therapy, and intraoperative radiation therapy in borderline resectable pancreatic adenocarcinoma 60
Germinal BRCA1-2 pathogenic variants (gBRCA1-2pv) and pancreatic cancer: epidemiology of an Italian patient cohort 60
Development of Educational Print Materials for Physical Activity in Cancer: Evaluation of Readability and Suitability 60
Risk and severity of SARS-CoV-2 infection in breast cancer patients undergoing a structured infection screening program at the University and Hospital Trust of Verona 60
"Pure" hepatoid tumors of the pancreas harboring CTNNB1 somatic mutations: a new entity among solid pseudopapillary neoplasms 60
PROFILing non-small-cell lung cancer patients for treatment with crizotinib according to anaplastic lymphoma kinase abnormalities: translating science into medicine. 59
KRAS wild-type pancreatic ductal adenocarcinoma: molecular pathology and therapeutic opportunities 59
Signal transduction pathways as therapeutic targets in cancer therapy 58
IL CARCINOMA POLMONARE A GRANDI CELLULE 58
New aromatase inhibitors as second-line endocrine therapy in postmenopausal patients with metastatic breast carcinoma 58
Lack of growth inhibitory synergism with combined MAPK/PI3K inhibition in preclinical models of pancreatic cancer 58
ASO Author Reflections: Preoperative Nutritional Care: The 'Cinderella' of Surgical Management in Patients with Pancreatic Cancer 58
Dosimetric Feasibility Study of Dose Escalated Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (LAPC) Patients: It Is Time to Raise the Bar 58
Targeting KRAS: The Elephant in the Room of Epithelial Cancers 58
Body composition parameters, immunonutritional indexes, and surgical outcome of pancreatic cancer patients resected after neoadjuvant therapy: A retrospective, multicenter analysis 57
Chemotherapy in non-small cell lung cancer patients after prior immunotherapy: The multicenter retrospective CLARITY study 57
Histo-molecular characterization of pancreatic cancer with microsatellite instability: intra-tumor heterogeneity, B2M inactivation, and the importance of metastatic sites 57
The Sequential Radiographic Effects of Preoperative Chemotherapy and (Chemo)Radiation on Tumor Anatomy in Patients with Localized Pancreatic Cancer 56
Morphologic and Molecular Landscape of Pancreatic Cancer Variants as the Basis of New Therapeutic Strategies for Precision Oncology 56
First-line erlotinib and fixed dose-rate gemcitabine for advanced pancreatic cancer. 55
Totale 7.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 80.029
article - articoli 79.395
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 634
Totale 160.058
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020351 0 0 0 0 0 0 38 36 52 51 57 117
2020/20211.111 93 259 52 122 146 119 37 34 43 25 110 71
2021/20221.789 110 378 60 108 46 22 37 103 59 37 310 519
2022/20234.070 290 364 383 714 323 1.057 61 223 440 49 105 61
2023/20242.607 91 167 234 360 225 356 206 191 56 126 419 176
2024/20253.325 438 354 332 1.393 349 302 157 0 0 0 0 0
Totale 14.866